Targeted Oncology

Cabozantinib is an inhibitor of multiple receptor tyrosine kinases (RTKs) with roles in cancer pathogenesis. This review focuses on data relevant to the use of cabozantinib tablets (Cabometyx®) in the treatment of hepatocellular carcinoma (HCC) in …

Focal adhesion kinase (FAK), also known as protein tyrosine kinase 2 (PTK2), is a non-receptor cytokine tyrosine kinase that comprises a structural component of focal adhesions. These focal adhesions are protein complexes containing cell surface …

Cellular interactions with the extracellular matrix play a pivotal role in tumor initiation, progression, and metastasis [ 1 ]. Focal adhesion kinase [FAK; also known as protein tyrosine kinase 2 (PTK2)] is a widely expressed, nonreceptor …

Focal adhesion kinase (FAK)/protein tyrosine kinase 2 is a ubiquitous, non-receptor, cytoplasmic tyrosine kinase that localizes to areas of focal adhesion where the plasma membrane makes contact with the extracellular matrix [ 1 – 4 ]. FAK is a key …

Bladder cancer is the fourth most common cancer in men and the ninth most common in women in the Western world. The management of bladder carcinoma requires a multidisciplinary approach. Optimal treatment depends on several factors, including …